C-WZUKMSC-derived extracellular vesicles, cell-free therapy, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aegle Therapeutics MSC-derived extracellular vesicles, cell-free therapy, regenerative medicine
Aegle Therapeutics is a clinical-stage developer of cell-free therapies using extracellular vesicles to deliver natural biomolecular payloads. Its platform focuses on regenerative, immunomodulatory, and anti-inflammatory effects, with AGLE-102 being studied for recessive dystrophic epidermolysis bullosa and other severe dermatological disorders.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Aegle Therapeutics — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic